Viridian Therapeutics, Inc.\DE (VRDN) stock
VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)
Close on Nov 18, 2026Market cap $3.41BP/E –Yield –
Viridian Therapeutics, Inc.\DE r&d expenses
Research and development expenses are spending on new products and technology.
Viridian Therapeutics, Inc.\DE's R&D Expenses for the twelve months ending Jun 30, 2026 was $324.68M, up 6.6% year over year. For fiscal 2025 it was $338.93M, up 42.3% from the year before. Over ten years it grew 79.0% a year on average. The highest annual figure on record is $338.93M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $338.93M | +42.3% |
| FY2024 | Dec 31, 2024 | $238.25M | +49.1% |
| FY2023 | Dec 31, 2023 | $159.77M | +58.3% |
| FY2022 | Dec 31, 2022 | $100.89M | +77.4% |
| FY2021 | Dec 31, 2021 | $56.89M | +101.0% |
| FY2020 | Dec 31, 2020 | $28.30M | -18.7% |
| FY2019 | Dec 31, 2019 | $34.79M | +14.4% |
| FY2018 | Dec 31, 2018 | $30.42M | +55.0% |
| FY2017 | Dec 31, 2017 | $19.62M | +43.3% |
| FY2016 | Dec 31, 2016 | $13.69M | +1266.5% |
| FY2015 | Dec 31, 2015 | $1.00M | +188.8% |
| FY2014 | Dec 31, 2014 | $347.00K | +54.2% |
| FY2013 | Dec 31, 2013 | $225.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $71.58M | -17.4% |
| Q1 FY2026 | Mar 31, 2026 | $77.63M | +1.0% |
| Q4 FY2025 | Dec 31, 2025 | $89.21M | +24.0% |
| Q3 FY2025 | Sep 30, 2025 | $86.26M | +24.7% |
| Q2 FY2025 | Jun 30, 2025 | $86.63M | +54.2% |
| Q1 FY2025 | Mar 31, 2025 | $76.84M | +87.7% |
| Q4 FY2024 | Dec 31, 2024 | $71.96M | +86.6% |
| Q3 FY2024 | Sep 30, 2024 | $69.16M | +127.6% |
| Q2 FY2024 | Jun 30, 2024 | $56.19M | +40.2% |
| Q1 FY2024 | Mar 31, 2024 | $40.94M | -19.3% |
| Q4 FY2023 | Dec 31, 2023 | $38.56M | -1.9% |
| Q3 FY2023 | Sep 30, 2023 | $30.39M | +37.4% |
| Q2 FY2023 | Jun 30, 2023 | $40.08M | +84.6% |
| Q1 FY2023 | Mar 31, 2023 | $50.74M | +185.9% |
| Q4 FY2022 | Dec 31, 2022 | $39.32M | +75.6% |
| Q3 FY2022 | Sep 30, 2022 | $22.12M | +172.4% |
| Q2 FY2022 | Jun 30, 2022 | $21.71M | +72.8% |
| Q1 FY2022 | Mar 31, 2022 | $17.75M | +28.5% |
| Q4 FY2021 | Dec 31, 2021 | $22.39M | +46.8% |
| Q3 FY2021 | Sep 30, 2021 | $8.12M | +161.0% |
| Q2 FY2021 | Jun 30, 2021 | $12.57M | +227.6% |
| Q1 FY2021 | Mar 31, 2021 | $13.81M | +126.2% |
| Q4 FY2020 | Dec 31, 2020 | $15.25M | +81.2% |
| Q3 FY2020 | Sep 30, 2020 | $3.11M | -65.5% |
| Q2 FY2020 | Jun 30, 2020 | $3.84M | -55.4% |
| Q1 FY2020 | Mar 31, 2020 | $6.10M | -30.3% |
| Q4 FY2019 | Dec 31, 2019 | $8.42M | +2.2% |
| Q3 FY2019 | Sep 30, 2019 | $9.03M | +22.0% |
| Q2 FY2019 | Jun 30, 2019 | $8.60M | +2.7% |
| Q1 FY2019 | Mar 31, 2019 | $8.75M | +36.5% |
| Q4 FY2018 | Dec 31, 2018 | $8.23M | +64.7% |
| Q3 FY2018 | Sep 30, 2018 | $7.40M | +47.4% |
| Q2 FY2018 | Jun 30, 2018 | $8.38M | +52.6% |
| Q1 FY2018 | Mar 31, 2018 | $6.41M | +55.7% |
| Q4 FY2017 | Dec 31, 2017 | $5.00M | +28.0% |
| Q3 FY2017 | Sep 30, 2017 | $5.02M | +69.2% |
| Q2 FY2017 | Jun 30, 2017 | $5.49M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.12M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.91M | – |
| Q3 FY2016 | Sep 30, 2016 | $2.97M | – |
See a number that looks wrong?